Enhancing quality
of life by Biodesign
Dr Andrew Morris is part of the Biodesign team
Biodesign is a partnership of leading experts in degenerative disease and regenerative medicine producing radical new approaches to regenerative medicine that will enhance patient quality of life and treatment outcomes.
Funded by an €11m collaborative multi-site project award under the EU's FP7 programme, Biodesign brings together biomolecular and pharmaceutical scientists at Nottingham's UK and Malaysia campuses, in collaboration with leading research groups from around Europe.
Led by Professor Stephen Doughty, the Biodesign researchers at UNMC will develop porous microparticles utilising a number of novel approaches to particle production. The Malaysia team is also spearheading the Biodesign outreach activities in the Australasian region. UNMC is already managing the MYEULINK initiative, an EU funded three-year project based in Malaysia, which aims to increase awareness and understanding of the EU and its key policies among universities, government officials, the private sector, the media and other interest groups in Malaysia.
Dr Andrew Morris is part of the Biodesign team. He said: "The Biodesign project is one of the largest single awards ever made to researchers at the Malaysia Campus. The School of Pharmacy hopes to build on this success and cement itself as one of the leading Pharmacy Schools for research in South East Asia."